首页> 美国政府科技报告 >Defining the Molecular Actions of Dietary Fatty Acids in Breast Cancer: Selective Modulation of Peroxisome Proliferator-Activated Receptor Gamma. Addendum; Final rept. 30 Sep 2006-8 Apr 2008
【24h】

Defining the Molecular Actions of Dietary Fatty Acids in Breast Cancer: Selective Modulation of Peroxisome Proliferator-Activated Receptor Gamma. Addendum; Final rept. 30 Sep 2006-8 Apr 2008

机译:定义膳食脂肪酸在乳腺癌中的分子作用:过氧化物酶体增殖物激活的受体γ的选择性调节。附录;最终的评论。 2006年9月30日至2008年4月8日

获取原文

摘要

Stark differences in the actions of linoleic acid (LAA), an omega-6 fatty acid, and eicosapentaenoic acid (EPA), an omega-3 fatty acid, on breast cancer tumors have been described. We propose that transactivation of peroxisome proliferators-activated receptor gamma (PPAR.) mediates the physiological effects of different dietary fatty acids on breast cancer. PPAR. plays a role in the development and progression of breast cancer tumors. We have shown that individual ligands of PPAR. can selectively activate PPAR. in three different ways. Selective activation of PPAR. by a single ligand occurs between tissue types and between individual breast cancer cell lines. Also, unique ligands selectively activate PPAR. within a single cell type. We propose that fatty acids will elicit their effects on breast cancer cells in a similar manner. Using both pharmaceutical and molecular approaches we have demonstrated that PPAR. serves as a molecular target for both LAA and EPA. Our data shows that fatty acids utilize PPAR. to activate a PPAR response element reporter system and that the receptor is both sufficient and necessary to observe this response. Also, EPA treatment increases the ability of PPAR. to bind to DNA. Furthermore, through multiple approaches we have determined that fatty acids do not need to be converted to prostaglandins but themselves can function as PPAR. ligands. To date, we have determined that both LAA and EPA act as PPAR. agonists. The objective of future studies will be to demonstrate that LAA and EPA act as selective PPAR. modulators (SPARMs) in breast cancer cells. We hypothesize that, though both LAA and EPA are PPAR. agonists, they function as SPARMs by causing unique gene expression and that this is in part the mechanism responsible for the different physiological actions of these fatty acids. We have also demonstrated that rosigli.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号